TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07269769: A Phase III , Randomized, Double-blind, Placebo-Controlled, Ranibizumab Injection Loading, Multicenter Clinical Trial Comparing the Efficacy and Safety of Sanhuang Jingshiming Pills in Subjects With nAMD

Sponsor: Tasly Pharmaceutical Group Co., Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 450 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07269769 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07269769 Rescue Dossier →